Full-Time

Corporate Business Development Leader – Director/Sr. Director/Executive Director

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$257k - $314kAnnually

Senior, Expert

San Bruno, CA, USA

Requires a 5-day onsite commitment.

Category
Business Development
Business & Strategy
Requirements
  • Advanced degree (e.g., M.B.A., Ph.D., etc.) with a relevant technical degree preferred with 12+ years of biopharma business development or related experience
  • Deal sheet with demonstrated record of leading negotiations to successful completion, including deals for regional rights (Asia, Europe, LATAM, MENA) and for late-clinical stage/commercial programs Preferably with an established network of contacts in the area of specialty cardiology
  • Ability to summarize or simplify complex concepts and to “think on your feet.”
  • Excellent analytical capabilities (e.g., to identify/evaluate opportunities, deal comparables, etc.)
  • Strong interpersonal and communication skills. Multilingual a plus
  • Demonstrated creativity, flexibility and problem-solving ability
  • Strong knowledge base regarding business development practices and trends
  • Proven ability to work effectively in a team environment with interactions across diverse disciplines
  • Positive attitude, attention to detail and polished presentation skills essential
  • This position is based in South San Francisco and requires a 5-day onsite commitment
Responsibilities
  • Source licensing and collaboration opportunities that align with Cytokinetics’ pipeline and strategic interests
  • Drive the deal process and decision-making, including generating and delivering impactful presentations to senior management and key decision-makers
  • Lead cross-functional deal teams involved in assessments and due diligence, building the business case, developing/recommending deal structures and negotiating term sheets and definitive agreements
  • Travel as needed to attend meetings/conferences and for networking and negotiations
  • Cross-train, coach and mentor colleagues within Business Development/Alliance Management, External Innovation (e.g., research collaborations/in-licensing) and other functions at Cytokinetics on opportunity assessment, due diligence, negotiation and driving activities towards decisions and deal execution.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?